HEALTHDAILY MAIL
SMALL CAP IDEA: Poolbeg Pharma and the oral drug that could unlock cancer immunotherapy's biggest problem
Poolbeg Pharma is developing an oral drug aimed at addressing a major challenge in cancer immunotherapy. The treatment could potentially enhance the effectiveness of existing immunotherapy approaches.
Related Signal
Adjacent reporting
- Scientists create “smart” DNA drug that targets cancer cells with extreme precision
- Thousands of cancer patients in England to benefit from new immunotherapy jab
- Pancreatic cancer was once considered almost untreatable. A new drug is offering hope
- Scientists supercharge immune cells to destroy cancer more effectively
- Pancreatic cancer: Dr. Pudlarz praises 'new generation targeted therapy' that inhibits gene mutation
- Pancreatic cancer breakthrough as scientists develop new drug that 'doubles survival rate' of silent killer